Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Omada Health in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Omada Health’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054840
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total cost of revenue | 24,048 | 21,065 | 53,403 | 44,128 |
| Gross profit | 63,787 | 40,306 | 112,480 | 72,206 |
| Operating expenses | ||||
| Research and development (4) | 14,625 | 10,024 | 27,322 | 18,830 |
| Sales and marketing (5) | 29,888 | 22,318 | 56,675 | 42,488 |
| General and administrative (6) | 15,725 | 12,308 | 29,715 | 23,628 |
| Total operating expenses | 60,238 | 44,650 | 113,712 | 84,946 |
| Operating income (loss) | 3,549 | (4,344) | (1,232) | (12,740) |
Item 1. Financial Statements
FAQ
- What is Omada Health's R&D?
- Omada Health (OMDA) reported R&D of $14.63M in Q2 2026.
- How has Omada Health's R&D changed year-over-year?
- Omada Health's R&D increased by 45.9% year-over-year, from $10.02M to $14.63M.
- What is the long-term trend for Omada Health's R&D?
- Over 2 years (2023 to 2025), Omada Health's R&D has grown at a 9.8% compound annual growth rate (CAGR), from $33.74M to $40.68M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Omada Health's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude